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arrhythmogenic right ventricular cardiomyopathy
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Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disorder characterized by 
fibrofatty replacement of the right ventricular myocardium and associated arrhythmias that originate from 
the right ventricle.  BIN1 is a membrane-associated protein that is involved in cardiac T-tubule 
homeostasis and is down-regulated in cardiomyopathy.  BIN1 has also been shown to be essential to the 
differentiation of myoblasts and the induction of skeletal muscle T-tubule invagination.
We hypothesized that BIN1 is released into the circulation and that circulatory BIN1 would 
provide useful cardiac monitoring data on patients suffering from heart failure in ARVC.  The objective 
was to determine whether plasma BIN1 can measure disease severity in patients with ARVC.
The study presented is a retrospective cohort of 24 patients with ARVC.  Plasma BIN1 levels 
were quantified and analyzed against clinical data to determine its ability to predict cardiac functional 
status and ventricular arrhythmias.  Mean plasma BIN1 levels were decreased in ARVC patients 
compared to controls (37 ± 1 vs. 60 ± 10, p < 0.05).  In a cross-sectional analysis, ARVC patients with 
heart failure had lower BIN1 (15 ± 7 vs. 60 ± 17 in patients without heart failure, p < 0.05). BIN1 levels 
correlated inversely with ventricular arrhythmia burden (R = -0.46, p < 0.05), and low BIN1 correctly 
classified patients with advanced heart failure or ventricular arrhythmia (ROC Area under the curve, 
AUC, 0.88 ± 0.07).
Low BIN1 also predicted future ventricular arrhythmias (ROC AUC 0.89 ± 0.09).  In a stratified 
analysis, BIN1 predicted future arrhythmias in patients without severe heart failure to an accuracy of 
82%.  In ARVC patients with serial blood draws who had evidence of disease progression during follow 
up, plasma BIN1 decreased by 63% (p < 0.05).  
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ARVC was first described in 1977 as an anatomical and clinical entity1 characterized by the 
replacement of cardiomyocytes by adipose and fibrous tissue that results in recurrent ventricular 
arrhythmias and right and/or left ventricular dysfunction2.  Historically, it was originally believed to be 
the result of a developmental defect in the right ventricular myocardium and was thus originally 
categorized as a dysplasia3, though these views have since changed.
The first patients presented with advanced disease, as early disease is usually asymptomatic.  
These patients were vulnerable to symptomatic arrhythmias originating from the right ventricle, as well as 
a higher risk of sudden cardiac death.  The arrhythmias range from isolated premature ventricular beats to 
sustained ventricular tachycardia (VT) or fibrillation (VF) , and were most often triggered by effort4.  
Arrhythmogenicity can be present with or without the classic fibrofatty myocardial changes on histology, 
which occurs transmurally in the right ventricle and localizes to the inflow tract, outflow tract, or right 
ventricular apex, leading to the progressive loss of right ventricular function.  Interestingly, despite being 
coined a right ventricular disorder, the fibrofatty replacement eventually spreads to the ventricular septum 
and the left ventricle, resulting in biventricular failure.  Left ventricular involvement occurs more 
frequently than previously thought, with recent reports of up to 76% of cases showing left ventricular 
pathology5.
ARVC is a familial disorder, and occurs at a prevalence of approximately 1 in 2000 to 1 in 5000, 
affecting men more often than women at a ratio of 3:16.  It is most often inherited in an autosomal 
dominant fashion with both reduced penetrance and variable expression, but can occasionally be seen as 
an autosomal recessive disorder7, 8.  The majority of ARVC phenotypes are caused by mutations in 
desmosome function9, but have also been found to arise from non-desmosomal proteins such as TGF-B3 
(a cytokine), RyR2 (which releases calcium from the myocardial sarcoplasmic reticulum), and 
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transmembrane protein 43 (an adipogenic transcription factor).  The following are the known mutations of 
ARVC:
Table A.  Mutations in ARVC (from OMIM: Online Mendelian Inheritance in Man)
ARVC type Chromosome/locus Gene codes Mode of transmission
ARVC 1 14q23-q24 TGFB-3 Autosomal dominant
ARVC 2 1q42-q43 RyR2 Autosomal dominant
ARVC 3 14q12-q22 Autosomal dominant
ARVC 4 2q32 Autosomal dominant
ARVC 5 3p23 Transmembrane protein 43 Autosomal dominant
ARVC 6 10p12-p14 Autosomal dominant
ARVC 7 10q22 Autosomal dominant
ARVC 8 6p24 Desmoplakin (DSP) Autosomal dominant
ARVC 9 12p11 Plakophilin-2 (PKP2) Autosomal dominant
ARVC 10 18q12 Desmoglein-2 (DSG2) Autosomal dominant
ARVC 11 18q12.1 Desmocollin-2 (DSC2) Autosomal dominant
ARVC 12 17q21 Plakoglobin (JUP) Autosomal dominant
Naxos Disease 17q21 Plakoglobin (JUP) Autosomal dominant
Diagnosis has refined significantly over the years.  The original diagnostic criteria were published 
in 1994 and were based on echocardiographic, histological, electrocardiographic, and family history 
findings10.  These criteria changed recently in 2010, with modifications made to take into account 
advances in genetics and diagnostic modalities11.  The current diagnostic criteria include:
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I.  Global or regional dysfunction and/or structural alteration as determined by 2D 
echocardiogram, MRI, or RV angiography
II.  Less than 60% residual myocytes by morphometric analysis, with or without fatty 
replacement of tissue on endomyocardial biopsy
III.  Repolarization abnormalities on electrocardiogram in the form of inverted T-waves in the 
right precordial leads or beyond individuals greater than 14 years of age in the absence of 
complete RBBB
IV.  Depolarization/conduction abnormalities on electrocardiogram in the form of an epsilon 
wave; i.e., reproducible low-amplitude wave forms between the QRS and T waves
V.  History of non-sustained or sustained ventricular tachycardia
VI.  Family history of ARVC confirmed in a first-degree relative by the current criteria, by 
pathologic examination, or identification of a causative mutation
Though our genetic understanding and diagnostic techniques have advanced considerably 
throughout the years, risk stratification remains fairly primitive.  Patients are generally stratified based on 
individual patient history and presentation, which remains a profound limitation on the prevention of 
adverse events, especially considering how catastrophically the patients can present.  Those who are 
considered high risk for arrhythmic death include patients who have been resuscitated from sudden 
cardiac death, very young patients, patients who have syncoped, and left ventricular involvement12.  Other 
clinical signs of high risk disease includes signs of right heart failure or left ventricular dysfunction or 
history of VT13.
Several invasive indicators have also been described, such as inducible VT, drug failure during 
several electrophysiologic studies, and RV dilation14.  The last ten years have seen promising non-
invasive stratifiers emerge, including QRS dispersion > 40 ms or QT dispersion > 65 ms.  However, even 
considering these advances, it is still difficult to predict future arrhythmia burden in ARVC patients or 
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which of the patients will develop progressive heart failure.  A non-invasive test that correlates with heart 
health and predicts risk of clinical progression would be of considerable clinical utility.
BIN1
Bridging Integrator 1 (BIN1) is a member of the BAR domain superfamily whose gene encodes 
multiple alternately spliced membrane adaptor proteins15-17.  It was originally identified in a 2-hybrid 
screen for proteins that interact with the MYC oncoprotein, and was eventually found to have tumor 
suppressor activity by inhibiting MYC18.  It was later described to have structural similarities to the breast 
cancer-associated autoimmune antigen Amphiphysin (AMPH), including a nuclear localization signal, an 
SRC homology-3 (SH3) domain, a MYC-interacting domain, and a BAR (Bin1/Amphyphysin/RVS167) 
domain19.  The BIN1 gene product expresses in several different tissues in the body, including prostate, 
brain, bone marrow, peripheral lymphoid tissues, skin, breast, gastrointestinal epithelium, and skeletal 
myocytes20.  The gene itself is comprised of twenty different alternatively spliced exons that can produce 
at least ten different isoforms.
Originally believed to be a gene involved in malignancy and cell cycle control, BIN1 was found 
to be down-regulated in 14 of 27 carcinoma cell lines and 3 of 6 primary breast tumors19.  It was later 
determined that BIN1 had a function in myoblast differentiation: upregulation of the BIN1 protein and 
mRNA were associated with differentiation of murine myoblasts, whereas BIN1 localized exclusively to 
the nucleus in undifferentiated cells.  These overexpressor-differentiators grew slower than control 
myoblasts and differentiated rapidly19.  In differentiated striated muscle, BIN1 is concentrated at T-
tubules, and was found to be sufficient to induce tubular plasma membrane invaginations.  In summary, a 
new role for BIN1 has been described in skeletal muscle cells: it is found to express in high levels during 
the differentiation of skeletal myocytes, and to be sufficient to induce T-tubule formation in non-
myocytes21.
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These basic findings have found clinical correlates.  In 2011, it was demonstrated that alternative 
splicing of BIN1 was disrupted in skeletal myocytes derived from patients with myotonic dystrophy19.  
Specifically, a loss of exon 11 correlated with little or no T-tubule formation in culture myocytes; 
consequently, it was postulated that the phosphatidylinositol 5-phosphate-binding site contained in exon 
11 was necessary for BIN1’s membrane tubulating activity.  Predictably, expressing the abnormal BIN1 
variant in mice resulted in abnormal T-tubules and decreased muscle strength.
More recently, BIN1's influence has also been found to extend to cardiomyocytes.  Our group has 
found that BIN1 is necessary for localizing the delivery of L-type calcium channels to T-tubules in 
cardiac T-tubules22, a function that is important for maintaining normal calcium transients and myocardial 
contractility23, 24.  Furthermore, our studies show that heart failure results in a reduction of the 
transcription and total BIN1 content in cardiomyocytes25.  An important structural feature of BIN1 is that 
it is a membrane attached protein, which makes it susceptible to release from the cell via membrane 
turnover.  Many cells in the body such as platelets26, 27, leukocytes28, and endothelial cells29 release small 
vesicles of membrane together with membrane-associated proteins into the blood as microparticles.  
These particles and their associated proteins have the potential for becoming biomarkers of cardiovascular 
disease31-33.  The reduction of cardiac BIN1 in failing hearts25 and its existence as a membrane associated 
protein22 prompted us to explore whether BIN1 is available in the blood in patients with failing hearts and 
whether plasma BIN1 is a direct measure of cardiomyocyte health.
Our first cohort of patients with failing hearts was that of patients with ARVC. The ARVC 
population has several advantages. Progressive fibrosis and loss of cardiomyocytes in ARVC, even if 
subclinical, will result in reduction of cardiac origin BIN1, which could be reflected in the blood levels of 
this protein.  In addition, ARVC patients typically have less non-cardiac involvement in their disease 
process34, 35 relative to most heart failure patients, have received full clinical work-ups, and are followed 
closely. Also, the occurrence of arrhythmia in these patients presents the opportunity to assess clinical 
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outcomes distinct from heart failure. Therefore, we tested the hypothesis that plasma BIN1 levels would 
correlate with disease severity and predict future arrhythmia events in patients with ARVC.  The results 
demonstrate that plasma BIN1 can assay cardiac health, with prognostic insight into both heart failure 
progression and development of ventricular arrhythmias
11
STATEMENT OF PURPOSE
The intent of this work is to determine whether serum BIN1 can be used to measure disease 
severity in patients with ARVC.
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HYPOTHESIS AND SPECIFIC AIMS
Similar to how intracellular BIN1 varies with heart failure, plasma BIN1 is predicted to measure 
overall cardiomyocyte health in ARVC.
The specific aims are to:
1) Determine if BIN1 is detectable human plasma.




The study was approved by the institutional review boards of the hospitals of University of 
California San Francisco (UCSF) and Johns Hopkins University (Western IRB, with clinical data 
collected via a Johns Hopkins protocol). All participating patients gave informed consent. The cohort 
consisted of thirty-one patients with a diagnosis of ARVC. The majority of the patients in this cohort 
(29/31) were established patients in the electrophysiology clinics at the time of the blood draw. Two 
patients had blood drawn at the referral visit.  Many patients were referred to these clinics by outside 
cardiologists or after ARVC was diagnosed in a family member. Several patients were hospitalized at 
UCSF or Johns Hopkins after an initial arrhythmic event. All ECGs and echocardiograms were performed 
at UCSF and Johns Hopkins. If an MRI, angiogram, or right heart biopsy was performed at an outside 
facility, the primary data was reviewed at UCSF or Johns Hopkins in order to establish the diagnosis of 
ARVC.
Patients were included in the study if a diagnosis of ARVC could be confirmed with available 
data according to the modified International Task Force Criteria35 by two separate cardiologists blinded to 
the assay results. Exclusion criteria included inadequate data to confirm diagnosis or presence of
ventricular tachycardia (VT) storm or several defibrillation events at the time of the blood draw, which 
might be expected to cause spurious BIN1 measurement.  
Of the initial 31 patients with a possible diagnosis of ARVC, 24 were included in the final 
analysis. Three (3) patients were excluded based on incomplete data and three (3) for failure to meet 
diagnostic criteria. One (1) patient with active VT storm and several defibrillation events on the day of the 
lab draw was also excluded. The patient characteristics are displayed in Table 1.  
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A control group consisted of 48 age, sex, and BMI-matched healthy controls without diabetes, 
hypertension or history of cardiac disease. These controls were identified from a large UCSF database 
containing clinical data and plasma specimens from healthy volunteers. All participants gave consent to 
future use of these specimens.
Measurement of plasma BIN1
Venous blood samples were drawn between April 2004 and January 2011. Seven patients had two 
blood samples drawn at separate time points. All follow up blood samples were drawn during routine 
clinical care. The samples were obtained and centrifuged at 4000 rpm for 20 minutes at 4ºC, and plasma 
stored in -80ºC freezer for later ELISA analysis.
A commercial ELISA reagent set (BD Bioscience, San Diego, CA) was used to design a highly-
sensitive ELISA test to quantify BIN1 in human plasma. This assay system uses two antibodies against 
human BIN1. A mouse monoclonal anti-BIN1 (1:500 in coating buffer, Sigma, St. Louis, MO) was used 
as the capture antibody and a primary goat anti-BIN1 antibody (1:500 in 1% BSA, Everest, Clifton, NJ) 
was used as the detection antibody. BIN1 standards were generated from lysates of 293FT cells 
overexpressing exogenous human BIN1. A standard curve (R2>0.98) was generated to determine the 
relative amount of BIN1 in each sample. The determined plasma concentration of BIN1 of each 
individual was normalized to and expressed as percent of BIN1 value in plasma pooled from three 25 
year-old healthy male adults. This assay is highly reproducible with an intra-assay variability of < 5%. 
Plasma BIN1 levels were then measured in duplicate from all ARVC and control samples. For patients 
with serial blood draws, the earliest sample drawn was used for the cross-sectional analysis.
Measurement of baseline characteristics and outcomes in ARVC patients
All clinical data were obtained by persons blinded to the BIN1 assay results. Baseline New York 
Heart Association (NYHA) class, RV and LV function, and ventricular arrhythmia history were recorded 
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for each patient. NYHA class was obtained from chart review, RV and LV function were determined by 
echocardiography. Right ventricular function was recorded as normal or mild, moderate or severe 
dysfunction. Ventricular arrhythmia history was obtained from chart review and ICD interrogation data.
To quantify each patient’s number of arrhythmia events, the following system was used. For 
patients who had an ICD placed for secondary prevention (n=10) due to history of aborted sudden cardiac 
death (hemodynamic collapse associated with sustained ventricular tachycardia/ventricular fibrillation) or 
sustained VT (>30 seconds) observed on Holter monitor or in an inpatient setting, the index event was 
counted as one event. Once an ICD was placed, (n=23), subsequent appropriate ICD therapy for sustained 
VT or ventricular fibrillation (VF) was counted as one event (even if several therapies were required for 
termination), and hospitalization for persistent VT or VT storm was weighted as 1.5 events to account for 
the more severe clinical manifestation. For patients with serial draws, NYHA class, interval arrhythmia 
history and LV and RV function at the time of the second lab draw were also recorded. New right 
ventricular dysfunction was defined as an interval change from normal to any degree of RV dysfunction 
(mild, moderate, or severe). Worsening right ventricular dysfunction was defined as any increase in RV 
dysfunction grade.
Statistics
Prism 5 software (GraphPad) was used for all statistical analysis. Data are expressed as mean ± 
SE.  A two-tail non-parametric Mann Whitney Test was used for comparison of BIN1 between the control 
and ARVC groups.  For comparison of BIN1 between heart failure patients and healthy controls, a two-
tail student’s t-test was used with Welch’s correction for significant different variances from the two 
groups.  To test for correlations between BIN1 and baseline continuous variables, Spearman analyses 
were performed.  Non-parametric Receiver-Operator Curve (ROC) analyses was used to determine the 
sensitivity and specificity of BIN1 values to diagnose patients with severe baseline disease and to test for 
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prediction of future arrhythmia events.  For comparison of serial BIN1 levels within the same patients, a 
paired two-tail student’s t-test was performed.
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RESULTS
Patient characteristics and baseline BIN1 levels
There were no statistically significant differences between the 24 ARVC patients and 48 controls 
with respect to age, gender, or BMI (Table 1).  Of the 24 ARVC patients, 21 met at least 2 major criteria 
and 3 patients met 1 Major and 2 minor criteria for diagnosis. Eight (33%) had a confirmed family history 
of ARVC, defined as either autopsy confirmation of ARVC or clinically confirmed diagnosis of ARVC in 
a family member. Of the patients who underwent genotype analysis, 11/15 (73%) were gene positive 
(Table 1).
At the baseline blood draw, 16 (70%) had at least one ventricular arrhythmia event, 7 (30 %) 
were NYHA class II or greater, and 4 (18%) were NYHA class III or IV. Four patients (18 %) had 
moderate to severe RV dysfunction. Twenty-three of the 24 patients had ICDs, with an average length of 
follow up after ICD placement of 4.4 ± 4.3 years to the time of the initial blood draw. Of the patients with 
ICDs, 13 (57 %) were placed for primary prevention and 10 (43%) were placed for secondary prevention.  
Plasma BIN1 did not significantly correlate with age, sex or BMI in the ARVC or control 
populations. As the metabolism kinetics and clearance of plasma BIN1 protein is not yet known, we 
analyzed plasma BIN1 against GFR to exclude the possibility of BIN1 changes with renal dysfunction. 
We found that BIN1 is not associated with renal function (Table 2). Furthermore, the mean plasma BIN1 
level in the ARVC population was 37 ± 1 with a median value of 17, as compared to controls with a mean 
of 60 ± 10 and a median of 27 (p < 0.05) (Table 1).
Cross-sectional analysis of BIN1 in patients with heart failure and arrhythmia
Within the ARVC population, we explored measured BIN1 against the absence (NYHA class I) 
or presence (NYHA class II-IV) of symptomatic heart failure. In ARVC patients with symptomatic heart 
failure, the mean BIN1 level was 15 ± 7 (n=7), whereas in ARVC patients without clinical heart failure 
the mean BIN1 level was 60 ± 17 (n=15), (p <0.05). Results are in Figure 1. Note plasma BIN1 levels 
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were not different between control patients without failing hearts, and ARVC patients who did not have 
heart failure. Spearman analyses were performed to assess for correlation of plasma BIN1 with baseline 
continuous clinical variables (Table 2). For patients with multiple samples, the first sample was used in 
this analysis. Plasma BIN1 levels inversely correlated with number of accumulated ventricular arrhythmia 
events (Rho of -0.60, p < 0.01) up to the point of the first plasma measurement (Table 2), but not with the 
length of ICD follow up, indicating an effect separate from an implanted ICD. To further control for the 
length of ICD implantation in each patient, the plasma BIN1 was analyzed against the average annual 
number of ventricular arrhythmia events. Consistently, plasma BIN1 inversely correlates with the average 
annual number of ventricular arrhythmia events (Rho of -0.46, p <0.05), independent of the presence of 
an ICD.
To assess the ability of plasma BIN1 to distinguish between patients with severe and mild ARVC, 
a Receiver-Operator-Curve analysis was performed (Figure 2). Severe ARVC was defined as either 
NYHA class III/IV heart failure or >1 ventricular arrhythmia event, and by default, mild ARVC was 
defined as NYHA class I/II and ≤1 ventricular arrhythmia event. At a cutoff value of less than 33, plasma 
BIN1 had an 82% sensitivity and an 82% specificity for predicting NYHA class III/IV heart failure status 
or >1 ventricular arrhythmia event (ROC AUC of 0.88 ± 0.07). Thus low plasma BIN1 correlates with the 
occurrence of severe ARVC.   
Analysis of plasma BIN1 as a predictor of future arrhythmia events
Mean follow up after initial blood draw in the ARVC cohort was 3.3 ± 1.7 years. 23 of the 24 
ARVC patients had ICDs. An event was defined as VT or VF requiring termination. BIN1<30 predicted a 
high future arrhythmia rate (>0.5 arrhythmia events/year, Figure 3) with a sensitively of 83%, specificity 
of 88% and an accuracy of 85 % (ROC AUC of 0.89 ± 0.09). Of the 23 patients with ICDs implanted, 
there were only 3 “failures” of the BIN1 test to classify patients in the appropriate high or low risk group. 
Two patients with BIN1 <30 did not have a high arrhythmia rate, and one patient with a BIN1 >30 
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continued to have high arrhythmias. Given the observed correlation of BIN1 with baseline heart failure 
and the known increase risk of arrhythmias in patients with heart failure, a stratified analysis was 
performed according to heart failure status at baseline. In patients with NYHA class I or II (n=20), BIN1< 
30 predicted future arrhythmia event rate with a sensitivity of 83%, specificity of 80 % and an accuracy of 
82 % (ROC AUC of 0.82 ± 0.14). In patients with NYHA class I (n=17), 8 of 17 had no history of 
ventricular arrhythmias and 10 of 17 had ICDs placed for primary prevention.  A BIN1<30 predicted a 
future high arrhythmia event rate with a sensitivity of 82%, specificity 67% and an accuracy of 79% 
(ROC AUC of 0.76 ± 0.21). NYHA class II or greater heart failure at baseline alone conferred an 
unadjusted relative risk of 3.61 (95 % CI 1.25-10.37, p<0.05) for high future arrhythmia events (heart 
failure follow-up are not available).
BIN1 in ARVC patients with serial blood draws  
Serial blood samples were available in seven ARVC patients and three controls (Figure 4). 
Overall, BIN1 values decreased in patients with progressive ARVC. Patient 1 developed new RV 
dysfunction and had her first episode of VF. Patient 2 developed worsening RV dysfunction, and had 
multiple VF events. Patient 3 had a continued high arrhythmia burden (3.8 events/year) and developed 
new RV dysfunction. At the time of the initial blood draw, patient 4 did not meet criteria for ARVC, 
however during follow up the patient developed new T wave inversion in ECG leads V1-V3 and an 
epsilon wave in V1, palpitations with a high non-sustained VT burden on Holter monitor. She has since 
had an ICD placed for confirmed ARVC but has not had sustained VT or VF, heart failure, or ventricular 
dysfunction. Patient 5 had a decrease in LV function from 70% to 49% and the progression from mild to 
moderate RV dysfunction. Patient 6 had mild RV dysfunction at baseline, but developed moderate RV 
dysfunction and 5 separate ventricular arrhythmia events. Patient 7 developed mild RV dysfunction 
during follow up and has had high ventricular arrhythmia rate (2.1events/year). In sum, patients with 
clinical progression had marked decreases in their plasma BIN1 levels (decrease of 63%, p<0.05). In 
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contrast, in serial samples from the three healthy controls (Figure 4), there was no significant change in 
BIN1 levels over a two year interval.
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DISCUSSION
In this study we describe a novel assay for plasma BIN1 and demonstrate that a single 
measurement of this protein can categorize disease severity in patients with ARVC and predict future 
arrhythmias with excellent test characteristics.  Our data show that lower plasma BIN1 levels occur in 
patients with clinical heart failure and correlate with a high burden of ventricular arrhythmias. 
Furthermore, in patients without heart failure, BIN1 predicts a high future arrhythmia rate with a 
sensitivity of 82% and a specificity of 67%.  Plasma BIN1 is not affected by renal function, age, gender, 
or BMI.  In ARVC patients with serial blood draws, plasma BIN1 decreased over time or remained low. 
Taken together, the data indicate that BIN1 correlates with cardiac health and inversely with 
arrhythmogenic potential.
It remains unclear why plasma BIN1 is lower in patients with more severe disease, but one 
possible explanation is that BIN1 expression correlates with cardiomyocyte or volume in the heart, and 
the loss of cardiomyocytes in ARVC after fibrofatty replacement results in significant reductions in the 
circulatory release of BIN1 into the myocardium.  An interesting experiment that would suggest this 
would be to examine chronic circulatory BIN1 levels in patients who have undergone myocardial 
infarction; presumably, these patients would also have lower BIN1 levels due to decreased numbers of 
cardiomyocytes, though this idea has yet to be explored.  A second possibility is that the cardiomyocytes 
may simply be producing less BIN1, as it has been demonstrated that diseased cardiomyocytes generate 
less BIN1 protein overall25.  A third contributing factor could be that diseased cardiomyocytes may be 
metabolically quiescent and turn over membrane protein at a slower rate.  Cell based studies will be 
important to determine which of these three possibilities is the major reason that plasma BIN1 is reduced 
in patients with diseased hearts.  A fourth possibility is that the alteration of other serum proteins in 
chronic heart failure may alter the half-life of circulatory BIN1, either by protein stability or
ubiquitination pathways.  
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An intriguing result of this study is that low BIN1 predicted a risk of ventricular arrhythmia even 
without the presence of advanced heart failure. We cannot rule out that arrhythmias occurred secondary to 
the new development of heart failure, but a more likely scenario is that low BIN1 can correlate to 
myocardium with a heterogeneous distribution of disease which would have a more arrhythmogenic than 
mechanical consequence. While arrhythmogenicity of ARVC is frequently ascribed to loss of ventricular 
desmosomal proteins and subsequent impairment of Cx43 based gap junction coupling, heterogeneity of 
gap junction coupling is critical to the occurrence of unidirectional block and initiation of reentrant 
arrhythmias36.  ARVC classically involves non-homogeneous involvement on myocardium, and therefore 
reduced BIN1 can detect foci of diseased and uncoupled heart while overall contractile function is 
preserved.
Furthermore, reduction in BIN1 may correlate with arrhythmogenesis independent of Cx43 
expression.  As a T-tubule associated protein, BIN1 is not a component of the cardiac desmosome. It is 
increasingly recognized that ARVC arrhythmogenecity may include non-desmosomal proteins37, altered 
intracellular calcium handling38, 39 and altered stress-related signaling cascades40. Thus BIN1-detectable 
pathologic remodeling of the cardiomyocyte (heterogeneous or otherwise) may indicate pathologic 
cardiomyocyte remodeling prior to loss of cardiomyocyte contractile function.
Our study has several potential limitations.  There exist several splice variants of BIN141 that 
have been described in an array of cellular functions42, and our current assay may include detection other 
non-cardiac BIN1 as well.  However, the total plasma BIN1 was reduced in patients with clinical heart 
failure/ventricular dysfunction and/or electrophysiologic instability, indicating a cardiac health dominated 
BIN1 plasma measurement.  Our primary concern was whether BIN1 from skeletal myocytes were 
confounding our results; as such, we controlled for BMI, age, and gender.  We have not precluded the 
possibility that other confounding variables may exist.  A potential solution to the specificity of BIN1 
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detection is that a cardiac specific splice variant of BIN1 may exist, which would substantially increase 
the utility of the test as a marker for cardiovascular health.
With regard to the limitations from the study population, the ARVC cohort used in this study is 
more severely affected compared to other larger described cohorts34. Use of larger ARVC cohorts will 
help validate the clinical utility of a BIN1 assay.
Our findings indicate that a single measurement of BIN1 in blood can categorize disease severity 
and predict future arrhythmia events in patients with ARVC.  A well-designed prospective study of a 
larger group of patients will be necessary to validate this assay in ARVC disease monitoring and use in 
guiding treatment strategies. 
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FIGURE LEGEND
Figure 1. Plasma BIN1 is lower in ARVC with HF. Plasma BIN1 (mean±SE) is significantly lower in 
ARVC patients with symptomatic heart failure (15±7, NYHA II-IV, N=7), as compared to ARVC 
patients without heart failure (60±17, NYHA I, n=15). P<0.05. (Plasma BIN1 is expressed as percent of 
BIN1 in plasma pooled from three healthy 25 year old males.)
Figure 2. Plasma BIN1 predicts disease severity.  The Receiver-Operator-Curve analysis indicates that 
low plasma BIN1 predicts severe ARVC defined as either NYHA class III/IV or >1 ventricular 
arrhythmias. Plasma BIN1<33 (indicated by red arrow) had an 82% sensitivity and an 82% specificity for 
predicting patients with NYHA class III/IV heart failure or >1 ventricular arrhythmia event (ROC AUC 
of 0.88, SE +/- 0.07, P<0.01).
Figure 3. Plasma BIN1 predicts future ventricular arrhythmias. The Receiver-Operator-Curve 
analysis indicates that low plasma BIN1 predicts high future ventricular arrhythmias. Plasma BIN1<30 
(indicated by red arrow) predicted a high future arrhythmia rate (>0.5/year) with a sensitively of 83%, 
specificity of 88% and an accuracy of 85 % (ROC AUC of 0.89, SE +/- 0.09, P<0.01).
Figure 4. Plasma BIN1 decreases with ARVC progression. Serial plasma BIN1 values are shown in 
controls (black circles, n=3) and in ARVC patients (red squares, n=7). The plasma BIN1 remained similar 
in healthy controls (mean±SE from 65±20 to 72±28, NS) while experienced a significant reduction (63% 
decrease) in ARVC patients during disease progression (mean±SE from 80±32 to 30±17, p<0.05). BIN1 
values for ARVC patients were as follows (first draw, second draw):   patient 1 (237, 130), patient 2 (145, 
130), patient 3 (74, 35), patient 4 (52, <5), patient 5 (33, 16), patient 6 (10, 8), patient 7 (8, 9).  (Plasma 
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Table	  I:	  Baseline	  Characteris2cs	  of	  ARVC	  Pa2ents	  and	  Controls	  
Characteris2cs	   ARVC	  Pa2ents Controls	   p	  Value	  
(n=	  24) (n=48)
BIN1(mean,	  median,	  SD)
Mean 37.1	  +/-­‐10 60	  +/-­‐	  10 <0.05
Median	   17 27
Age	  (yrs)* 43	  +/-­‐	  15 47+/-­‐	  13 0.470
Sex
Male	   13 26
Female	   11 22
Body	  Mass	  Index	  * 25.4	  +/-­‐	  5.9 23.6+/1 0.200
History	  
Family	  history	  posiOve	   8	  (33%)
Rhythm	  
History	  of	  any	  sustained	  ventricular	  arrhythmias	   16	  (70%)
Avg.	  length	  of	  ICD	  follow	  up	  *	   4.4	  	  +/-­‐	  4.3	  
ICD	  placed	   23	  (96%)
Primary	  prevenOon	   13	  (57%)
Secondary	  prevenOon	   10	  (43%)
Heart	  Failure	  
NYHA	  class	  II	  or	  greater	   7	  (30	  %)
NYHA	  class	  III	  or	  IV	   4	  (18%)
Moderate	  to	  severe	  	  RV	  dysfuncOon 4	  (18%)
*	  Plus-­‐minus	  value	  is	  the	  mean	  +/-­‐	  SD.
Table	  2:	  BIN1	  Associa2on	  with	  Baseline	  Characteris2cs	  in	  ARVC	  pa2ents	  
Con2nous	  Variables	   Spearman's	  Rho p	  Value	  
Total	  ventricular	  arrythmias	  to	  2me	  of	  plasma	  draw	   -­‐0.590 <0.005
Ventricular	  arrhythmia	  rate	  to	  2me	  of	  plasma	  draw	  (events/yr.) -­‐0.460 <0.05
Length	  of	  diagnosis	   0.090 0.702
ARVC	  
Body	  Mass	  Index	   0.050 0.702
Age	   -­‐0.250 0.249
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